Clinolipid

Clinolipid Manufacturers

• Baxter Healthcare Corporation
  

  ×

  Clinolipid | Baxter Healthcare Corporation

  

  ---

  2.1 Use of an Inline Filter

  Fragments of the administration port membrane could be dislodged into the bag after spiking. Use a 1.2 micron inline filter during administration of CLINOLIPID injection (alone or as part of an admixture) to remove particulate matter or micro-precipitate contamination during administration of CLINOLIPID injection (alone or as part of an admixture). Particulate matter > 5 microns has the capability of obstructing blood flow through capillaries, which could lead to embolism and vascular occlusion. Do not use filters of less than 1.2 micron pore size with lipid emulsions.

  2.2 Important Administration Instructions

  Before opening the overwrap, check the color of the oxygen indicator. Compare color of the indicator to the reference color printed next to the OK symbol depicted in the printed area of the indicator label. Do not use the product if the color of the oxygen absorber/indicator does not correspond to the reference color printed next to the OK symbol.

  After opening the bag, use the contents immediately and do not store for a subsequent infusion.

  Visually inspect that the emulsion is a homogeneous liquid with a milky appearance. Inspect for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Do not connect flexible bags in series to avoid air embolism due to possible residual gas contained in the primary bag.

  Air embolism can result if residual gas in the bag is not fully evacuated prior to administration if the flexible bag is pressurized to increase flow rates.

  Use of a vented intravenous administration set with the vent in the open position could result in air embolism.

  If CLINOLIPID injection is mixed with dextrose and/or amino acid solutions, check the compatibility before administration by inspecting the mixture closely for the presence of precipitates. Formation of precipitates could result in vascular occlusion.

  When infused alone, CLINOLIPID injection can be administered via central or peripheral vein. When administered with dextrose and amino acids, the choice of a central or peripheral venous route should depending on the osmolarity of the final infusate.

  Do not use administration sets and lines that contain di-2-ehtylhexyl phthalate (DEHP).

  2.3 Mixing Guidelines

  Prepare the admixture using strict aseptic techniques to avoid microbial contamination.

  Do not add additives directly to CLINOLIPID injection. Do not add CLINOLIPID injection to the total parenteral nutrition container first; destabilization of the lipid may occur from such an admixture.

  Do not use the EXACTAMIX Inlet H938173 with an EXACTAMIX compounder to transfer CLINOLIPID injection. This inlet spike has been associated with dislodgement of the administration port membrane into the CLINOLIPID injection bag.

  The following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic Dextrose Injections are not mixed with lipid emulsions alone:

  Transfer Dextrose Injection to the Total Parenteral Nutrition Admixture Container Transfer Amino Acid Injection Transfer Lipid Emulsion
  

  Amino Acid Injection, Dextrose Injection and Lipid Emulsions may be simultaneously transferred to the admixture container. Use gentle agitation during admixing to minimize localized concentration effects; shake bags gently after each addition.

  The prime destabilizers of emulsions are excessive acidity (such as a pH below 5) and inappropriate electrolyte content. Give careful consideration to additions of divalent cations (Ca++ and Mg++), which have been shown to cause emulsion instability. Amino acid solutions exert buffering effects that protect the emulsion.

  Inspect the admixture closely for separation of the emulsion. This can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The admixture should also be examined for particulates. Discard the admixture if any of the above is observed.

  2.4 Dosing Considerations

  The dosing of CLINOLIPID injection depends on energy expenditure, the patient’s clinical status, body weight, tolerance, and ability to metabolize CLINOLIPID injection, as well as additional energy given orally/enterally to the patient. For complete parenteral nutrition, concomitant supplementation with amino acids, carbohydrates, electrolytes, vitamins, and trace elements is necessary.

  Prior to administration of CLINOLIPID injection, correct severe water and electrolyte disorders, severe fluid overload states, and severe metabolic disorders. Before starting the infusion, obtain serum triglyceride levels to establish the baseline value. In patients with elevated triglyceride levels, initiate CLINOLIPID injection at a lower dose, and advance in smaller increments, checking the triglyceride levels prior to each adjustment.

  Adjust the administration flow rate by taking into account the dose being administered, the daily volume intake, and the duration of the infusion [see Overdosage (10)].

  The recommended duration of infusion for a parenteral nutrition bag is between 12 and 24 hours, depending on the clinical situation. Treatment with parenteral nutrition may be continued for as long as is required by the patient’s condition.

  The maximum daily dose of CLINOLIPID injection should be based on individual total nutritional requirements and patient tolerance. The usual lipid dosage is 1 to 1.5 g/kg/day (equal to 5 to 7.5 mL/kg/day of CLINOLIPID 20%) 1. The daily dose should not exceed 2.5 g/kg/day. The initial infusion rate should not exceed 0.1 g (equal to 0.5 mL) per minute for the first 15 to 30 minutes. If tolerated, gradually increase until reaching the required rate after 30 minutes.

  Close
  No Recall

  More Info